The Antibody Discovery Specialists.

We are antibody discovery enthusiasts discovering biologics for our partners against the most challenging classes of reagent and therapeutic targets, royalty-free!

Contact Us On The Twist Bioscience Website

100+ Successful mAb Discovery Campaigns Targeting Cell Surface receptors.

Abveris provides industry-leading antibody discovery solutions for therapeutic and reagent antibody developers. We have built a strong reputation on our ability to deliver outstanding science. We have custom-built gene-to-antibody discovery solutions to support development efforts for:

Therapeutic antibodies against difficult targets such as GPCR, ion channels, glycan targets

Cell therapies

Point-of-care diagnostics

Reagent & anti-idiotypic antibodies supporting clinical trials

Anywhere else antibodies are needed

Fee-for-service, royalty-free partnership model

Expertise in Antibody Discovery

Industry-leading platform for challenging targets

and royalty-free!

GPCR-1 Cell surface-1 High homology-2

Anti-id-1 cross reactive-2 Functional antibodies

End-to-End Antibody Discovery Technologies

Abveris is your premier antibody discovery specialist, offering end-to-end mAb discovery solutions to biotech and biopharma companies of all sizes.

Step 1:

Repertoire Generation

Step 2:

Advanced Screening

Step 3:

Advanced Characterization

Step 4:

Recombinant Expression

Step 5:

Humanization & Developability Assessment

Proprietary hyperimmune mouse model DiversimAb
Humanized mice
Alpaca (for VHH via B cell workflow)
Specialty immunization
Antigen production

Assay cell line development
Rapid, high-resolution single B cell screening via Beacon
Optimized hybridoma

Kinetic & epitope binning by Octet and Capterra
On-cell binding (iQue)
ELISA
Custom activity assays

Small to mid-scale production to support different discovery workflows
Validation of binding and function

High-throughput in silicon humanization
Developability and sequence liability assessment to guide lead candidate selection

The Reviews Are In.

Pharma and biotech of various sizes and pipelines rely on Abveris for antibody discovery.

At Promega, we struggled to acquire a high-affinity, high-specificity antibody against one target of interest. After failing with two previous vendors, we enlisted the help of Abveris and their DiversimAb approach, and we soon had a multitude of high-quality clones to choose from. We eventually chose a clone that far exceeded our expectations for performance. We were continually impressed by their high-quality analytical data, excellent communication, and overall collaborative spirit.

Promega

Our platform rapidly generates and validates new targets for treating challenging cancers. Working with Abveris will enable us to quickly identify and select highly specific antibodies for those targets, so that we can take the best antibody forward to address the needs of particular patient populations.

Jeff Goldberg, CEO

Immunitas Therapeutics

Contact the Antibody Discovery Specialists

Speak with Abveris scientists about how to tackle challenges in antibody discovery.

YOUR DISCOVERY PARTNER

The Mega Menu